An Investigator-initiated, Multi-center, Randomized, Double-blind, Placebo Controlled Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema
Latest Information Update: 25 Apr 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Acronyms DUPINUM
- 22 Apr 2024 Planned End Date changed from 31 Jan 2025 to 31 Jan 2027.
- 22 Apr 2024 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.
- 30 Aug 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.